Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

• Published in: The New England journal of medicine Vol. 380; no. 8; pp. 752 - 762
• Main Authors: Ridker, Paul M, Everett, Brendan M, Pradhan, Aruna, MacFadyen, Jean G, Solomon, Daniel H, Zaharris, Elaine, Mam, Virak, Hasan, Ahmed, Rosenberg, Yves, Iturriaga, Erin, Gupta, Milan, Tsigoulis, Michelle, Verma, Subodh, Clearfield, Michael, Libby, Peter, Goldhaber, Samuel Z, Seagle, Roger, Ofori, Cyril, Saklayen, Mohammad, Butman, Samuel, Singh, Narendra, Le May, Michel, Bertrand, Olivier, Johnston, James, Paynter, Nina P, Glynn, Robert J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 21.02.2019
• Subjects: Angina; Arteriosclerosis; Atherosclerosis; C-reactive protein; Cardiovascular disease; Cerebral infarction; Cytokines; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Disease prevention; Double-blind studies; Drug dosages; Folic acid; Health risk assessment; Heart attacks; Heart diseases; Hematocrit; IL-1β; Immunomodulators; Inflammation; Interleukin 6; Investigations; Liver; Metabolic syndrome; Methotrexate; Monoclonal antibodies; Myocardial infarction; Patients; Pharmaceuticals; Proteins; Rheumatoid arthritis; Skin cancer
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1809798

Patients with coronary artery disease were randomly assigned to either methotrexate (15 to 20 mg weekly) or placebo. At a median of 2.3 years, there was no difference between the two groups in the rate of myocardial infarction, stroke, or cardiovascular death.